INmune Bio Reports Positive Phase 2 Imaging Data for XPro1595 in Early Alzheimer's Disease

INmune Bio Inc. has announced new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595, a selective soluble TNF neutralizer, in patients with early Alzheimer’s disease and elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place December 1-4, 2025, in San Diego, California. The study evaluated changes from baseline at 24 weeks using PerpPD+, a grey matter imaging analysis, in participants with early Alzheimer’s disease and a high inflammatory burden. Secondary outcome measures included cortical disarray measurement (CDM), which showed a trend for reduced cortical disarray in dose-compliant participants. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9593961-en) on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)